RT Journal Article
SR Electronic
T1 T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259027
DO 10.1101/2021.06.17.21259027
A1 Phillip A. Swanson II
A1 Marcelino Padilla
A1 Wesley Hoyland
A1 Kelly McGlinchey
A1 Paul A. Fields
A1 Sagida Bibi
A1 Saul N. Faust
A1 Adrian B. McDermott
A1 Teresa Lambe
A1 Andrew J. Pollard
A1 Nicholas M. Durham
A1 Elizabeth J. Kelly
YR 2021
UL http://medrxiv.org/content/early/2021/07/13/2021.06.17.21259027.abstract
AB AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18–85 years who enrolled in the phase 2/3 COV002 trial. Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T-cell receptor (TCR) β sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses. Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.One Sentence Summary Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222Competing Interest StatementElizabeth Kelly, Nick Durham, and Kelly McGlinchey: employees of AstraZeneca and hold or may hold AstraZeneca stock. Paul Fields: financial interest in Adaptive Biotechnologies. Andrew Pollard: Chair of UK Dept. Health and Social Care (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in COVID19 vaccine policy discussions, and is a member of the WHO SAGE. AJP is chief investigator on clinical trials of Oxford University COVID19 vaccine funded by NIHR. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, NIHR or WHO Oxford University has entered a joint COVID19 vaccine development partnership with AstraZeneca. Phillip Swanson, Adrian McDermott, Marcelino Padilla, Wesley Hoyland, Teresa Lambe, Sagida Bibi, and Saul Faust: None to declare.Funding StatementUK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, The Bill and Melinda Gates Foundation, and AstraZeneca.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COV001 was approved in the UK by the Medicines and Healthcare products Regulatory Agency (reference 21584/0424/001-0001) and the South-Central Berkshire Research Ethics Committee (reference 20/SC/0145). COV002 was sponsored by the University of Oxford (Oxford, UK) and approved in the UK by the Medicines and Healthcare products Regulatory Agency (reference 21584/0428/001-0001) and the South-Central Berkshire Research Ethics Committee (reference 20/SC/0179). Vaccine use was authorized by Genetically Modified Organisms Safety Committees at each participating site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTCRβ immunosequencing data that support the findings of this study have been deposited at the publicly available immuneACCESS platform at: https://clients.adaptivebiotech.com/pub/